[ad_1]
TORONTO, February 8, 2019 / PRNewswire / – (PBT.U: CSE, PTGEF: OTC Markets) – Portage Biotech Inc. ("Portage" or the "Company") wishes to announce that due to an oversight, the The acquisition of SalvaRx was closed before obtaining final approval of the CST. However, the CSE informed the Company that this approval was imminent and that it would be announced by means of an exchange form. It is expected that the Exchange Bulletin will be released today for the negotiations to resume Monday, February 11. The last form 2A will be displayed before the resumption of operations.
Neither the TSA nor its market regulator (as defined in the policies of the TSA) badume any responsibility for the adequacy or accuracy of this release.
This press release may contain forward-looking statements with respect to the future operations of Portage Biotech Inc. (the "Company"). All forward-looking statements about the Company's future plans and activities, including management's badessment of the Company's expectations or beliefs, may be subject to certain badumptions, risks and uncertainties beyond the control of the Company. Investors are cautioned that such statements are not guarantees of future performance and that actual results and financial results may differ materially from estimates and projections.
See the original content: http: //www.prnewswire.com/news-releases/portage-biotech-inc—cse-toissue-bulletin-final-regarding-salvarx-acquisition-300792591.html
SOURCE Portage Biotech Inc.
[ad_2]
Source link
